SYRE
Spyre Therapeutics·NASDAQ
--
--(--)
--
--(--)
SYRE fundamentals
Spyre Therapeutics (SYRE) released its earnings on Aug 5, 2025: revenue was 0 (YoY --), met estimates; EPS was -0.49 (YoY +43.02%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.49
+43.02%
Report date
Aug 5, 2025
Earnings Call
7:00 AM on Aug 5, 2025
Meeting link.EPS
Actual | -14.25 | -10 | -7.25 | -8.75 | -7 | -2.5 | -7.75 | -7.75 | -9.25 | -6.75 | -4.3254 | -5 | -5 | -56.75 | -9.34 | -4.05 | -1.2 | -0.86 | -1.36 | -0.81 | -0.6 | -0.49 | |||||||||
Forecast | -16.2143 | -10.6786 | -9.7931 | -7.6786 | -5.7143 | -4.1088 | -6.9799 | -7.1875 | -8.5357 | -7.9461 | -6.25 | -5.7083 | -4.5 | -3.4847 | -0.6 | -0.7272 | -1.0489 | -0.9497 | -0.8243 | -0.9861 | -0.8411 | -0.7536 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +12.11% | +6.35% | +25.97% | -13.95% | -22.50% | +39.15% | -11.03% | -7.83% | -8.37% | +15.05% | +30.79% | +12.41% | -11.11% | -1528.55% | -1456.67% | -456.93% | -14.41% | +9.45% | -64.99% | +17.86% | +28.66% | +34.98% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 13.70M | 1.40M | 3.60M | 1.36M | 625.00K | 174.00K | 168.00K | 198.00K | 688.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 8.70M | 12.15M | 4.05M | 3.66M | 1.59M | 709.50K | 208.33K | 133.33K | 184.00K | 198.00K | 198.00K | 371.33K | 0 | 6.67M | 0 | 3.00M | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -100.00% | +12.72% | -65.46% | -1.63% | -14.47% | -11.91% | -16.48% | +26.00% | +7.61% | +247.47% | -100.00% | -100.00% | 0.00% | -100.00% | 0.00% | -100.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What factors drove the changes in Spyre Therapeutics's revenue and profit?What does Spyre Therapeutics do and what are its main business segments?What is Spyre Therapeutics's latest dividend and current dividend yield?Did Spyre Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Spyre Therapeutics's earnings call?What is Spyre Therapeutics's gross profit margin?What is the market's earnings forecast for Spyre Therapeutics next quarter?What guidance did Spyre Therapeutics's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
